Pharmacological treatment of cannabis dependence

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1351-1358

  Weinstein, A M ^a   Gorelick, David A ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cannabis; Dependence; Pharmacotherapy; Treatment; Withdrawal

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; ATOMOXETINE; BACLOFEN; BUSPIRONE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENTACAPONE; FLUOXETINE; LITHIUM; LOFEXIDINE; METHYLLYCACONITINE; MIRTAZAPINE; NALTREXONE; NEFAZODONE; PLACEBO; RIMONABANT; VALPROATE SEMISODIUM;

ARTICLE; CANNABIS ADDICTION; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; NEUROPHARMACOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SINGLE DRUG DOSE; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

ANIMALS; BUSPIRONE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MARIJUANA ABUSE; SEROTONIN RECEPTOR AGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 79960009173     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150846     Document Type: Article

References (91)

1. United Nations Office on Drugs and Crime (ONODC) World Drug Report 2010; United Nations Office on Drugs and Crime. http://unp.un.org
2. Substance Abuse and Mental Health Services Administration.Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856 Findings). Rockville, MD. 2010.
3. European Monitoring Centre for Drug and Drug addiction (EMCDDA) Conference proceedings: Identifying Europe's information needs for effective drug policy EMCDDA, Lisbon, December 2009; Luxembourg: Publications Office of the European Union ISBN 978- 92-9168-409-0 doi: 10.2810/26467 www.emcdda.europa.eu 2009.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association. 1994. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull 2002; 36(Suppl 2): 123-132.
5. World Health Organization (WHO) International Classification of Diseases, Tenth Revision (ICD-10) - Clinical Modification, 2007; WHO, Geneva.
6. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psycholl Med 2006; 36, 1447-1460.
7. Copeland J, Swift W, Roffman R, Stephens RS. A randomized controlle trial of brief cognitive- behavioral interventions for cannabis use disorder. J Subste Abuse Treat 2001; 21: 55-64.
8. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007; 32: 1220-1236.
9. Stephens RS, Roffman RA., Simpson, E.E. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol,.1994; 62: 92-99.
10. Stephens, R.S., Roffman, R.A., Curtin, LExtended versus brief treatment for marijuana use. J Consult Clin Psychol,. 2000; 68: 898-908.
11. Moore BA, Budney AJ Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat, 2003; 25, 85-89
12. Pertwee, R. GLigands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol, 2008; 13: 147-159.
13. Mechoulam, R. Cannabinoids as Therapeutic Agents, CRC Press, FL 1986.
14. Mechoulam, RMarijuana, Chemistry, Pharmacology, Metabolism and Clinical Effects Academic Press, New York. 1973.
15. Sarel, S., Mechoulam, R., Agranat, I. Trends in Medicinal Chemistry. Blackwell Publ. Oxford, UK. 1991.
16. Montoya, I.D., Vocci, F. Novel medications to treat addictive disorders. Curr Psychiat Rep. 2008; 10 (5): 392-8.
17. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleusaccumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacol (Berl) 1990;.102: 156-162.
18. Tanda G, Pontieri FE, Di Chiara G Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276: 2048-2050.
19. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L Fratta, W Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport; 2006;. 17: 1629-1632.
20. Bossong, M.G., van Berckel, B.N.M., Boellaard, R., Zuurman, L., Schuit, R.C., Windhurst, A.D., van Gerven, J.M.A., Ramsey, N.F., Lammertsma, A.A., Kah, R.S. Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacol, 2009; 34, 759-766.
21. Stokes, P.R.A., Mehta, M.A., Curran, H.V., Breen, G., Grasby, P.MCan recreational doses of THC produce significant dopamine release in the humn striatum? Neuroimage,. 2009; 48, 186-190.
22. Stokes, P.R.A., Egerton, A., Watson, B., Reid, A., Breen, G., Lingford- Hughes, A., Nutt, D.J., Mehta, M.A. Sinificant decreases in frontal and temporal [11C]- raclopride binding after THC challenge. Neuroimage, 2010; 52, 1521-1527.
23. Jaffe, J.H Drug addiction and drug abuse. In A.G. Gilman, L.S. Goodman & F. Murad (Eds). The Pharmacological Basis of Therapeutics. (7th Edition) USA: Macmillan. 1985.
24. Huestis, M.A., Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T., Frank, R.A Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arc Gen Psychiat,.2001; 58 (4): 322-8.
25. LeFoll, B, Gorelick, DA, Goldberg, S The future of endocannabinoid- oriented clinical research after CB1 antagonists. Psychopharmacol, 2009; 205(1): 171-174.
26. Budney, AJ., Hughes, JR., Moore, B.A., Vandrey, R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiat, 2004; 161, (11), 1967-1977.
27. Budney, A.J., Hughes, J.R. The cannabis withdrawal syndrome. Curr Opin Psychiat, 2006; 19; 233-238.
28. American Psychiatric Association DSM V development (www.dsm5.org).
29. Budney, A. J., Radonovich, K. J., Higgins, S. T., Wong, C. J. Adults seeking treatment for marijuana dependence: a comparison with cocaine- dependent treatment seekers. Exp Clin Psychopharmacol, 1998; 6 (4); 419-426.
30. Budney, A.J., Moore, B.A., Vandrey, R.A., Hughes, J.R Onset, magnitude, and duration of abstinence effects following heavy marijuana use. Drug Alc Dep,. 2002; 66, S23.
31. Budney, A.J., Hughes, J.R., Moore, B.A. & Novy, P.L. Marijuana abstinence effects in mariujana smokers maintained in thein home environment. Arc Gen Psychiat 2001; 58; 917-924.
32. Stephens, R.S., Roffman, R.A., Simpson, E.E Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol,. 1994; 62; 92-99.
33. Stephens, R.S., Roffman, R.A., Curtin, LExtended versus brief treatment for marijuana use. J Consult Clin Psychol,. 2000; 68: 898-908.
34. Levin, K.H., Copersino, M.L., Heishman, S.J., Liu, F., Kelly, D.L., Boggs, D.L., Gorelick, D.A. Cannabis withdrawal symptoms in nontreatment- seeking adult cannabis smokers. Drug and Alc Dep, 2010; 111: 120-127.
35. Hart, C.L. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alc Dep, 2005; 80; 147-159.
36. Nordstrom, B.R., Levin, F.R Treatment of cannabis use disorders: a review of the literature. Am J Add,. 2007; 16 (5); 331-42.
37. Benyamina, A., Lecacheux, M., Blecha, L., Reynaud, M., Lukasiewcz, M Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expt Rev in Neurotherapy,. 2008; 8 (3): 479-91.
38. Vandrey, R., Haney, M Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs;. 2009; 23(7): 543-53.
39. [39] Löscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs; 2002;. 16: 669-694.
40. Artigas, F., Nutt, D.J., Shelton, R. Mechanism of action of antidepressants. Psychopharmacol Bull; 2002; 36 (Suppl 2): 123-132.
41. Dwoskin, L.P., Rauhut, A.S., King-Pospisil K.A., Bardo, M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev, 2006; 12; 178-207.
42. Haney M, Ward, A.S., Comer, S.D., Hart, C.L., Foltin, R.W., Fischman, M.W. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacol, 2001; 155: 171-179.
43. Haney, M., Hart, C.L., Vosburg, S.K., et al Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacol, 2004; 29; 158-170.
44. Haney, M., Hart, C.L., Ward, A.S., Foltin, R.W Nefazodone decreased anxiety during marijuana withdrawal in humans. Psychopharmacol (Berl), 2003; 165; 157-165.
45. Budney, A.J., Vandrey, R.G., Hughes, J.R., Moore, B.A., Bahrenburg, B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alc Dep, 2007; 86 (1): 22-9.
46. Levi, M.S., Borne, R.FA review of chemical agents in the pharmacotherapy of addiction. Curr Medic Chem,.2002; 9: 1807-1818.
47. Haney, M., Hart, C.L., Vosburg, S.K., Comer, S.D., Reed, S.C., Foltin, R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacol, 2008; 197; 157-168.
48. Akhondzadeh, S., Ahmadi-Abhari, S.A., Assadi, S.M., Shabestari, O.L., Kashani, A.R., Farzanehgan, Z.M. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiate withdrawal. J Clin Pharmacol Therap, 2000; 25; 347-353.
49. Liappas, J. Paparrigopoulos, T., Tzavellas, E., Rabavilas, A. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol, 2005; 29: 55-60.
50. Yoon, S.J., Pae, C.U., Kim, D.J., Namkoong, K., Lee, E., Oh, D.Y., Lee, Y.S., Shin, D.H., Jeong, Y.C., Kim, J.H., Choi, S.B., Hwang, I.B., Shin, Y.C., Cho, S.N., Lee, H.K., Lee, C.T. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. Prog Neuropsychopharmacol, 2006; 30: 1196-1201.
51. Haney, M., Hart, C.L., Vosburg, S.K., Comer, S.D., Collins, S., Reed, S.C., Cooper, Z., Foltin, R.W Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacol, 2010; 211;, 233-244.
52. Levin, F.R., Kleber, H.D Use of dronabinol for cannabis dependence: two case reports and review. Am J Add. 2008; 17: 161-164.
53. Comer, S.D., Sullivan, M.A., Yu, E., Rothenberg, J.L., Kleber, H.D., Kampman, K., Dackis C., O'Brien, C.P. Injectable, Sustained- Release Naltrexone for the Treatment of Opioid Dependence A Randomized, Placebo-Controlled Trial. ArcGen Psychiat, 2006; 63: 210-218.
54. Huestis, M.A., Boyd, S.J., Heishman, S.J., Preston, K.L., Bonnet, D., Le Fur, G., Gorelick, D.A Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacol (Berl). 2007; 194 (4): 505-15.
55. Clapper, J.R., Mangieri, R.A., Piomelli, D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacol, 2009; 56 Suppl 1: 235-43.
56. Wachtel, S.R., de Wit, H Naltrexone does not block the subjective effects of oral Delta(9)- tetrahydrocannabinol in humans. Drug Alc Dep., 2000; 59; 251-260.
57. Haney, M., Bisaga, A., Foltin, R.WInteraction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacol, 2003; 166: 77-85.
58. Greenwald, M.K., Stitzer, M.L Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alc Dep, 2000; 59; 261-275.
59. Haney, M Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacol, 2007; 32: 1391-1403.
60. Cooper, Z.D., Haney, MO pioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacol (Berl),.2010; 211(2): 141-8.
61. Koob, G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci, 1992; 13; 177-184.
62. Di Chiara, G., North, R.A. Neurobiology of opiate abuse. Trends Pharmacol Sci, 1992; 13; 185-193.
63. Wise, R.A. Neurobiology of addiction. Curr op Neurobiol, 1996; 6, 243-251.
64. Volkow, N.D., Wang, G.J., Fowler, J.S., Hitzemann, R., Angrist, B., Gatley, S.J., Logan, J., Ding, Y.S., Pappas, N.Association of Methylphenidate- induced craving with changes in right striatoorbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiat, 1999; 156 (1); 19-26.
65. Caspi, A., Moffitt, T.E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton R., Craig, I.W. Moderation of the effect of adolescent-onsetcannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiat,. 2005; 57(10); 1117-1127.
66. Zammit, S., Spurlock, G., Williams, H., Norton, N., Williams, N., O'Donovan, M.C., Owen, M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interaction with tobacco and cannabis use. Brit J Psychiat, 2007; 191; 402-407.
67. Shafa, RCOMT- Inhibitors may be a Promising Tool in Treatment of Marijuana Addiction Trials. A J Addict,. 2009; 18: 322.
68. Kau KS, Madayag A, Mantsch JR, et al. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine induced drug seeking. Neuroscience. 2008; 155; 530-537.
69. LaRowe, S.D., Mardikian, P., Malcolm, R., Myrick, H., Kalivas, P., McFarland, K., Saladin, M., McRae, A., Brady, K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addictn. 2006; 15; 105-110.
70. Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystineglutamate exchange in nicotine dependence in rats and humans. Biol Psychiat.; 2009; 65: 841-845.
71. Gray, K.M., Watson, N.L., Carpenter, M.J., Larowe, S.D Nacetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Add, 2010; 19 (2): 187-9.
72. Wilens, T.E Attention Deficit Hyperactivity Disorder and Substance Use Disorders. AJ Psychiat, 2006; 163; 2059-2063.
73. Tirado, C.F., Goldmanm M., Lynch, K., Kampman, K.M., Obrien C.P. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alc Dep, 2008; 94; 254-257.
74. McRae-Clark A.L., Carter R.E., Killeen T.K., Carpenter M.J., White K.G., Brady K.T. A Placebo-Controlled Trial of Atomoxetine in Marijuana-Dependent Individuals with Attention Deficit Hyperactivity Disorder. Am J Add, 2010; 19 (6); 481-489.
75. Blier, P., Bergeron, R., de Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacol, 1997; 16(5): 333-8.
76. Gobert, A., Rivet, J.M., Cistarelli, L., Melon, C, Millan, M.J. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2- adrenergic receptors underlie its actions. Neuroscience, 1999; 93(4): 1251-62.
77. McRae, A.L., Brady, K.T., Carter, R.E Buspirone for Treatment of Marijuana Dependence: A Pilot Study. Am J Add,. 2006; 15: 404.
78. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alc Dep, 2009; 105 (1-2): 132-8.
79. Cui, S.S., Bowen, R.C., Gu, G.B., Hannesson, D.K., Yu, P.H., Zhang, X. Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J Neurosci; 2001; 21; 9867-9876.
80. Bowen R, McIlwrick, J., Baetz, M., & Zhang, X Lithium and marijuana withdrawal. Can J Psychiat,.2005; 50; 240-241.
81. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol, 2009; 23: 84-93.
82. Levin, F.R., McDowell, D., Evans, S.M., Nunes, E., Akerele, E., Donovan, S., Vosburg, S.K. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Add, 2004; 13; 21-32.
83. Carpenter, K.M., McDowell, D., Brooks, D.J., Cheng, W.Y., Levin, F.R. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Add, 2009; 18(1): 53-64.
84. Petronis, K.R., Samuels, J.F., Moscicki, E.K., Anthony, J.C. An epidemiologic investigation of potential risk factors for suicide attempts. Soc Psychiat Psychiat Epidem, 1990; 25; 193-199.
85. Rowe, M.G., Fleming, M.F., Barry, K.L., Manwell, L.B., Kropp, S. Correlates of depression in primary care. Journal of Family Practice, 1995; 41: 551-558.
86. Sarel, S., Mechoulam, R., Agranat, I. Trends in Medicinal Chemistry. Blackwell Publ. Oxford, UK. 1991.
87. Cornelius, J.R., Clark, D.B., Bukstein, O.G., Bimaher, B., Salloum, I.M., Brown, S.A. Acute phase and five year follow up study of fluoxetine in adolescents with major depression and comorbid substance abuse disorder: a review. Add Behavs, 2005; 30; 1824-1833.
88. Cornelius, J.R., Buksteinb, O.G., Douaihy, A.B., Clark, D.B., Chung, T.A., Daley, D.C., Wood, D.S., Brown, S.J. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alc Dep, 2010; 112: 39-45
89. Dhawan, K., Kumar, S., Sharma, A Reversal of cannabinoids (delta9- THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction. Jf Pharm Pharmacol,.2002; 54(6): 875-81.
90. Solinas, M., Scherma, M., Fattore, L., Stroik, J., Wertheim, C., Tanda, G., Fratta, W., Goldberg, S.RNicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci,. 2007; 27(21): 5615-20.
91. Schlosburg, J.E., Carlson, B.L., Ramesh, D., Abdullah, R.A., Long J.Z., Cravatt, B.F., Lichtman, A.H. Inhibitors of endocannabinoidmetabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J, 2009; 11(2): 342-52.